97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details


臨床試験数 : 2,527 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04576000
(ClinicalTrials.gov)
August 25, 202017/9/2020Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative ColitisPhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)Ulcerative ColitisDrug: Janus Kinase InhibitorAlimentiv Inc.Alimentiv Translational Research ConsortiumRecruiting18 YearsN/AAll40United States;Belgium;Canada;Italy;Netherlands;Spain
2EUCTR2019-003780-21-NL
(EUCTR)
04/05/202021/02/2020Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC Study) Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC Study) Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: XELJANZ
Product Name: Janus kinase Inhibitor
INN or Proposed INN: Janus kinase Inhibitor
Alimentiv Inc.NULLNot RecruitingFemale: yes
Male: yes
40Phase 4United States;Canada;Spain;Belgium;Netherlands;Italy